Skip to Primary Navigation

Skip to main content

FDA seeks comments on expedited CNPV pilot program

A photo of FDA Commissioner Marty Markay testifying before Congress
Photo: Anna Moneymaker/Getty Images

Kevin Kinsella

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The controversial Commissioner’s National Priorities Voucher program awards “ultra-fast” reviews for medications and biological products of strategic national importance while upholding the FDA’s standards.

The US Food and Drug Administration (FDA) is seeking public comment on the controversial Commissioner’s National Priority Voucher (CNPV) pilot program.

The CNPV pilot program was established in June 2025 to address “critical public health needs” by providing an “ultra-fast” review pathway for drugs and biological products of strategic national importance

, , , , , ,